Caris Molecular Intelligence®

Slides:

Advertisements

Similar presentations

James R. Rigas Comprehensive Thoracic Oncology Program

Advertisements

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D. September 6, 2014.

Metastatic Breast Cancer and Emerging Research Kathryn J. Ruddy, MD MPH Assistant Professor of Oncology Mayo Clinic.

New Therapies for Metastatic Breast Cancer Sigrun Hallmeyer, MD Oncology Specialists, SC Director, Oncology Specialists Research Institute Chair, Cancer.

Terapia targeted : limiti e successi nelle metastasi cerebrali 55 ° Congresso Nazionale SNO Como, Aprile, 2015 Riccardo Soffietti U. O. Neuro-Oncologia.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

Chemo-, hormonal-, and targeted therapy Dr. Judit Toth Department of Oncology Medical University of Debrecen.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

Fernando Cotait Maluf Diretor do Departamento de Oncologia Clínica Centro de Oncologia-Hospital São José Fernando Cotait Maluf Diretor.

Appropriate e sostenibili Alberto Sobrero IRCCS San Martino IST Genova Alberto Sobrero IRCCS San Martino IST Genova.

A novel 3D human tissue culture model

Overall survival in NSCLC

Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Cytotoxic Agents.

Cancer Chemotherapy Dr.Azarm.  The goal of cancer treatment is eradication of cancer  If not possible shifts to palliation,amelioration and preservation.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Evidence-guided tumor profiling to individualize therapy decisions.

ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.

Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group phase III trials Patricia.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

Recent Advances in NSCLC Treatment

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.

© The Author(s) Published by Science and Education Publishing.

Management of metastatic and recurrent head and neck cancer

N Engl J Med; Volume 373(17): ; October 22, 2015

Recent Advances in Breast Cancer

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and mutational analysis.

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

advanced lung adenocarcinoma subtype

MCW Regional Cancer Therapy Program

Bladder Cancer: A New Era in Treatment

بنام خداوند جان و خرد.

Early diagnosis of Lung Cancer

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Targeted Cancer Therapies

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Clinical Trial Available

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors Alexa B. Schrock,

Tania Tillett Royal United Hospital

Advanced NSCLC Without Actionable Mutations

Volume 147, Issue 2, Pages (November 2017)

Updates in Lung Cancer: Insights From Vienna

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Advancing Care Across the Spectrum of Pancreatic Cancer

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

John C. Morris, M.D. Professor

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Putting Evidence Into Practice: Highlights From Toronto

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Practical Guidance on the Management of Pan-Negative NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

MX39795 Study Design Category 1 R 3:1 Category 2 Inclusion criteria

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Third-Generation EGFR TKIs

Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal.

The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;

Physiologic vs Chronologic Age

Esteller, New England Journal of Medicine, 2008

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Physiologic vs Chronologic Age

Opening remarks Welcome to CUP 2019: Cancer of Unknown Primary in the Era of Precision Medicine Focus: Contemporary Clinical Management and International.

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Caris Molecular Intelligence® Table 2. Treatment Associations tested for all solid tumors Caris Molecular Intelligence® FoundationOne® OncoDEEP® Chemotherapy Antimetabolites (5-FU, pemetrexed, capecitabine) ✔ ✖ Anthracyclines (doxorubicin, epirubicin, liposomal-doxorubicin) Alkylating agents (temozolomide, dacrabazine) Nucleoside analog (gemcitabine) Platinum agents (cisplatin, carboplatin, oxaliplatin) Taxanes (docetaxel, paclitaxel) Topoisomerase inhibitors (Irinotecan, topotecan) Hormone Therapy Hormone therapy Androgen deprivation therapy Targeted Therapies ALK inhibitor (crizotinib) Antiangiogenic agents (bevacizumab) BRAF inhibitors (vemurafenib, dabrafenib) EGFR TKIs (erlotinib, gefitinib, afatinib) HER2-directed therapy (trastuzumab, T-DM1, pertuzumab, lapatinib) mTOR inhibitors (everolimus, temsirolimus) Small molecular kinase inhibitor (imatinib) Immunotherapy PD-1 inhibitors (nivolumab, pembrolizumab, atezolizumab) Clinical Trials Investigational Agents Jaume Capdevila et al. Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal. Journal of Cancer Research and Treatment, 2017, Vol. 5, No. 3, 77-85. doi:10.12691/jcrt-5-3-1 © The Author(s) 2015. Published by Science and Education Publishing.